Competitive playbook — how Eudaven wins against Hims, Ro, Calibrate, and Found

The plain-English version

This lesson is the operator-friendly tour of the strategic synthesis in data/kb/competitive/strategic-playbook.md. The full document is loaded into every brief synthesizer call — but you should know what's in it, because the same logic governs:

• The angle_hypothesis that briefs lead with
• The copy_polish "lead with personalization, clinician oversight, or pharmacy transparency" guidance
• The brand voice attributes that contrast with competitor patterns

When the pipeline produces a brief that surprises you, it's almost always because a counter-play in this playbook informed it.

The four competitors

The pipeline has detailed teardowns of four named competitors in data/kb/competitive/. Quick orientation:

• Hims & Hers — Public company, massive paid-acquisition machine, pivoting from compounded to branded following March 2026 Novo Nordisk settlement. Most visible competitor.
• Ro — Private, quiz-funnel-led intake, broader DTC platform (Ro for ED, weight-loss, etc.). Less GLP-1-specific positioning.
• Calibrate — Annual-commitment program with structured coaching. Higher price, higher LTV. Wellness-clinical hybrid voice.
• Found — Compounded-only model historically. Aggressive paid acquisition. Most exposed to the regulatory tightening.

The strategic playbook synthesizes ten patterns across these competitors. Each play has a competitor pattern, why it's failing now, and Eudaven's counter-play.

Quick reference to the ten plays

Play 1 — Sameness-with-branded framing

Theirs: "Same active ingredient as Wegovy, lower price." Failing because: Most-cited FDA violation in 2025-2026. Ours: Molecule + clinician, never sameness.

Play 2 — Speed-of-access as the hero benefit

Theirs: "Get your prescription in minutes." Failing because: 24HrDoc Feb 2026 warning letter; undermines 503A. Ours: Convenience post-evaluation, clinician as feature.

Play 3 — Price anchoring against branded

Theirs: Side-by-side tables vs. Wegovy list price. Failing because: SimpleRx warning; Hims/Novo settlement eroded gap. Ours: Absolute pricing with transparent inclusions.

Play 4 — Subscription lock-in

Theirs: Calibrate's 12-month commitment. Failing because: Patients increasingly aware of alternatives. Ours: Flexibility, transparent off-ramps, optional structure.

Play 5 — Paid social as primary acquisition

Theirs: Hims spends $100M+ on Meta + influencer. Failing because: Meta tightening, CAC rising, AG pressure. Ours: Trust-led organic + SEO, paid as amplification.

Play 6 — Compounded-only model

Theirs: Found's positioning, much of the field pre-2026. Failing because: Shortage list resolved, 503A discretion ended. Ours: Branded-first with compounded as the clinical bridge.

Play 7 — Async-only intake

Theirs: Hims, Ro questionnaire-only. Failing because: GLP-1 isn't low-complexity. Async-only looks like a corner being cut. Ours: Live clinician for first visit, async for follow-ups.

Play 8 — Transformation testimonials

Theirs: Before/after photos as headline creative. Failing because: Lumimeds warning; FTC Endorsement Guides. Ours: Process-led messaging, lifestyle imagery, no quantified outcomes.

Play 9 — Generic "weight loss" framing

Theirs: Everyone uses "weight loss" as the noun. Failing because: Reads transactional to sophisticated patients. Ours: Lead with metabolic health.

Play 10 — Aggressive paid + thin content moat

Theirs: Brand IS the funnel. No content depth. Failing because: CAC inflation + regulatory tightening + AG pressure all compounding. Ours: Content moat built in parallel with brand. Paid amplifies the highest-trust assets.

The throughline

Every Eudaven counter-play trades short-term CAC efficiency for long-term durability. In an environment where:

• The FDA is escalating enforcement
• Platforms are tightening (Meta categorization, Google certification)
• State AGs are pushing for more enforcement
• The public is becoming more sophisticated about compounded vs. branded

...durability wins. The playbook isn't a list of clever marketing tactics. It's a coherent strategic position: be the brand that makes sense in 2027 and 2028, not just in this quarter.

How the pipeline encodes this

The playbook isn't just a document — it's wired into the generation flow:

• The brief synthesizer loads the full playbook on every call, so every brief has the counter-positioning available as context.
• The brief synthesizer's user prompt explicitly directs: "Lead the angle_hypothesis with personalization, clinician oversight, or named-pharmacy transparency. Do NOT lead with insurance, price, or program flexibility — those are non-v2 frames." This wording is derived from the playbook.
• The compliance node enforces the don't-do-this half of the playbook (GLP1-001 sameness, GLP1-008 compounded-as-branded, etc.). The playbook tells us what to do instead.

What to do next

• Read the full playbook in data/kb/competitive/strategic-playbook.md for all ten plays with detailed rationale.
• Then GLP-1 gotchas for the enforcement-flavored version of the same patterns.
• Look at three Eudaven briefs and identify which plays inform them. This is one of the most useful exercises for understanding the pipeline's reasoning.